SCHEMBL13799409

SCHEMBL13799409

COc1ccc2c(c1)CC(C)C2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 8/20 0.56
DRD3 P35462 8/20 0.56
CYP19A1 P11511 1/20 0.53
ACHE P22303 1/20 0.51
HTR2C P28335 2/20 0.48
SLC6A4 P31645 1/20 0.48
HTR2B P41595 1/20 0.48
HTR6 P50406 1/20 0.48
DRD4 P21917 3/20 0.46
OPRM1 P35372 1/20 0.46
MTNR1A P48039 1/20 0.46
MTNR1B P49286 1/20 0.46
DRD1 P21728 2/20 0.46
DRD5 P21918 2/20 0.46
CHRNB2 P17787 1/20 0.45
CHRNB4 P30926 1/20 0.45
CHRNA3 P32297 1/20 0.45
CHRNA7 P36544 1/20 0.45
CHRNA4 P43681 1/20 0.45
HTR2A P28223 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16233623 1.00 DRD2 (0.56) DRD2DRD3CYP19A1ACHEHTR2C
SCHEMBL14279806 1.00 DRD2 (0.56) DRD2DRD3CYP19A1ACHEHTR2C
SCHEMBL16233625 0.85 DRD2 (0.58) DRD2DRD3CYP19A1ACHEDRD4
SCHEMBL16233624 0.85 DRD2 (0.58) DRD2DRD3CYP19A1ACHEDRD4
SCHEMBL629616 0.85 DRD2 (0.58) DRD2DRD3CYP19A1ACHEDRD4
SCHEMBL8983525 0.85 DRD2 (0.68) DRD2DRD3CYP19A1ACHEHTR2C
SCHEMBL29052203 0.82 DRD2 (0.51) DRD2DRD3CYP19A1ACHEHTR2C
SCHEMBL762709 0.82 DRD2 (0.51) DRD2DRD3CYP19A1ACHEDRD4
SCHEMBL762707 0.82 DRD2 (0.51) DRD2DRD3CYP19A1ACHEDRD4
SCHEMBL23343811 0.82 DRD2 (0.54) DRD2DRD3CYP19A1ACHEHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119497589-A Therapeutic combinations, compositions and methods for designing and producing conditions that promote mental well-being 心境设计实验室股份有限公司 2025-02-21 CN disclosed
US-11744785-B2 Use of volatile compositions to limit or eliminate the perception of malodor FIRMENICH SA (CH) 2023-09-05 US disclosed
US-20230233425-A1 USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR FIRMENICH SA (CH) 2023-07-27 US disclosed
US-20160219879-A1 FUNGICIDAL COMPOSITIONS SYNGENTA PARTICIPATIONS AG (CH) 2016-08-04 US disclosed
US-9326513-B2 Fungicidal compositions SYNGENTA PARTICIPATIONS AG (CH) 2016-05-03 US disclosed
US-20140335201-A1 FUNGICIDAL COMPOSITIONS SYNGENTA PARTICIPATIONS AG (CH) 2014-11-13 US disclosed
US-8623407-B2 Gabapentin-containing solid compositions and process for preparing the same PFIZER INC. (US) 2014-01-07 US disclosed
US-8623407-B2 Gabapentin-containing solid compositions and process for preparing the same PFIZER INC. (US) 2014-01-07 US disclosed
US-20090156677-A1 Gabapentin-containing Solid Compositions and Process for Preparing the Same PFIZER INC 2009-06-18 US disclosed
US-20090156677-A1 Gabapentin-containing Solid Compositions and Process for Preparing the Same PFIZER INC 2009-06-18 US disclosed
US-7309719-B1 Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid WARNER LAMBERT COMPANY, LLC (US) 2007-12-18 US disclosed
US-7309719-B1 Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid WARNER LAMBERT COMPANY, LLC (US) 2007-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11744785-B2 Use of volatile compositions to limit or eliminate the perception of malodor TAS2R8, TRPA1, TAS2R10 DRD2 380/4885DRD3 595/4885CYP19A1 2700/4885
US-20090156677-A1 Gabapentin-containing Solid Compositions and Process for Preparing the Same GABRD, GABRA6, GABRB1 DRD2 2060/4885DRD3 2441/4885CYP19A1 2250/4885
US-20140335201-A1 FUNGICIDAL COMPOSITIONS CYP1B1, CYP4B1, DDT DRD2 2150/4885DRD3 2305/4885CYP19A1 8/4885
US-20160219879-A1 FUNGICIDAL COMPOSITIONS CYP1B1, CYP4B1, DDT DRD2 2150/4885DRD3 2305/4885CYP19A1 8/4885
US-20230233425-A1 USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR TAS2R8, TRPA1, TAS2R10 DRD2 380/4885DRD3 595/4885CYP19A1 2700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.